Elanco Animal Health, Inc. (ELAN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1237109,
    "name": "Elanco Animal Health, Inc.",
    "stock_name": "Elanco Animal Health, Inc.",
    "full_name": "Elanco Animal Health, Inc.",
    "name_url": "stocks-analysis/elanco-animal-health-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "21.99",
    "chg": -0.19,
    "chgp": "-0.86%",
    "dir": -1,
    "prev_price": "22.18",
    "mcapval": "9,464.30",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US28414H1032",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "11.77 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/elanco-animal-health-inc-1237109-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Elanco Animal Health Hits New 52-Week High at $22.95",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/elanco-animal-health-hits-new-52-week-high-at-2295-3671536",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ElancoAnimalHea_priceRelatedfactors_3671536.png",
        "date": "2025-11-04 18:02:52",
        "description": "Elanco Animal Health, Inc. has achieved a new 52-week high of USD 22.95, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. Over the past year, the company has seen a notable increase, outperforming the S&P 500, while maintaining a favorable P/E ratio and manageable debt levels."
      },
      {
        "title": "Elanco Animal Health Hits New 52-Week High of $22.86",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/elanco-animal-health-hits-new-52-week-high-of-2286-3662022",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ElancoAnimalHea_priceRelatedfactors_3662022.png",
        "date": "2025-10-31 16:27:37",
        "description": "Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.86 on October 30, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has gained 23.74% over the past year, with a competitive P/E ratio of 14.00 and a manageable debt-to-equity ratio of 0.54."
      },
      {
        "title": "Elanco Animal Health Hits New 52-Week High of $22.73",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/elanco-animal-health-hits-new-52-week-high-of-2273-3659203",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ElancoAnimalHea_priceRelatedfactors_3659203.png",
        "date": "2025-10-30 18:50:39",
        "description": "Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.73 on October 29, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 23.85% increase over the past year, showcasing significant recovery and growth within its market."
      },
      {
        "title": "Elanco Animal Health Hits New 52-Week High of $22.25",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/elanco-animal-health-hits-new-52-week-high-of-2225-3649299",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ElancoAnimalHea_priceRelatedfactors_3649299.png",
        "date": "2025-10-27 17:02:34",
        "description": "Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.25 on October 24, 2025, reflecting strong performance with a 20.89% gain over the past year. The company has a market capitalization of USD 9,464 million and maintains a competitive P/E ratio and manageable debt levels."
      },
      {
        "title": "Is Elanco Animal Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-elanco-animal-health-inc-overvalued-or-undervalued-3637870",
        "imagepath": "",
        "date": "2025-10-21 12:10:38",
        "description": "As of 17 October 2025, the valuation grade for Elanco Animal Health, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 14, an EV to EBITDA of 12.07, and a PEG ratio of 0.03, which suggests limited growth relative to its price. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of approximately 19.25 and 15.17, respectively, indicating that Elanco's valuation is less favorable in the context of its industry.\n\nDespite strong recent performance, with a year-to-date return of 76.88% compared to the S&P 500's 13.30%, the long-term outlook appears less optimistic, as evidenced by a 5-year return of -32.09% against the S&P's 91.29%. This disparity in long-term performance further supports the conclusion that Elanco Animal Health, Inc. is currently ove..."
      },
      {
        "title": "Elanco Animal Health Experiences Valuation Adjustment Amid Competitive Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/elanco-animal-healths-valuation-grade-downgraded-from-very-attractive-to-expensive-3641070",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ElancoAnimalHea_valuationdot_3641070.png",
        "date": "2025-10-20 17:18:56",
        "description": "Elanco Animal Health, Inc. has recently adjusted its valuation, reflecting changes in financial metrics within the Pharmaceuticals & Biotechnology sector. The company reports a P/E ratio of 14 and a price-to-book value of 1.09, with notable returns on capital and equity. Its year-to-date stock performance has significantly outpaced the S&P 500."
      },
      {
        "title": "Is Elanco Animal Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-elanco-animal-health-inc-overvalued-or-undervalued-3634740",
        "imagepath": "",
        "date": "2025-10-20 12:27:52",
        "description": "As of 17 October 2025, Elanco Animal Health, Inc. has moved from a very attractive valuation grade to expensive. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 12.07, and a Price to Book Value of 1.09. In comparison to peers, Elanco's P/E ratio of 19.25 is higher than BioMarin Pharmaceutical, Inc., which has a P/E of 15.17, indicating that Elanco is trading at a premium relative to some of its competitors.\n\nDespite strong short-term returns, with a year-to-date return of 76.88% compared to the S&P 500's 13.30%, the long-term performance has been lackluster, with a 5-year return of -32.09% versus the S&P 500's 91.29%. This disparity suggests that while recent performance may seem promising, the overall valuation does not support continued growth at the current price levels...."
      },
      {
        "title": "Is Elanco Animal Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-elanco-animal-health-inc-overvalued-or-undervalued-3632278",
        "imagepath": "",
        "date": "2025-10-19 12:05:22",
        "description": "As of 17 October 2025, the valuation grade for Elanco Animal Health, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued, with a P/E ratio of 14, an EV to EBITDA ratio of 12.07, and a PEG ratio of 0.03, which suggests that while growth expectations are low, the current price may not reflect its intrinsic value adequately.\n\nIn comparison to its peers, Elanco's P/E ratio of 19.25 is higher than BioMarin Pharmaceutical, Inc. at 15.17, which is considered fairly valued, and significantly higher than Halozyme Therapeutics, Inc. at 15.92. Despite strong recent performance, with a year-to-date return of 76.88% compared to the S&P 500's 13.30%, the long-term outlook appears less favorable, as the 5-year return for Elanco is -32.09% versus the S&P 500's 91.29%. This discrepancy reinforces the notion that Elanco may be overvalued at its curr..."
      },
      {
        "title": "Elanco Animal Health Hits New 52-Week High at $21.76",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/elanco-animal-health-hits-new-52-week-high-at-2176-3604390",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ElancoAnimalHea_priceRelatedfactors_3604390.png",
        "date": "2025-10-08 16:58:06",
        "description": "Elanco Animal Health, Inc. achieved a new 52-week high of USD 21.76 on October 7, 2025, reflecting a strong upward trend from its low of USD 8.02. The company, with a market cap of approximately USD 9,464 million, operates in the Pharmaceuticals & Biotechnology sector and emphasizes growth."
      }
    ],
    "total": 21,
    "sid": "1237109",
    "stock_news_url": "https://www.marketsmojo.com/news/elanco-animal-health-inc-1237109"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Elanco Animal Health Hits New 52-Week High at $22.95

2025-11-04 18:02:52

Elanco Animal Health, Inc. has achieved a new 52-week high of USD 22.95, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. Over the past year, the company has seen a notable increase, outperforming the S&P 500, while maintaining a favorable P/E ratio and manageable debt levels.

Elanco Animal Health Hits New 52-Week High of $22.86

2025-10-31 16:27:37

Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.86 on October 30, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has gained 23.74% over the past year, with a competitive P/E ratio of 14.00 and a manageable debt-to-equity ratio of 0.54.

Elanco Animal Health Hits New 52-Week High of $22.73

2025-10-30 18:50:39

Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.73 on October 29, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 23.85% increase over the past year, showcasing significant recovery and growth within its market.

Elanco Animal Health Hits New 52-Week High of $22.25

2025-10-27 17:02:34

Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.25 on October 24, 2025, reflecting strong performance with a 20.89% gain over the past year. The company has a market capitalization of USD 9,464 million and maintains a competitive P/E ratio and manageable debt levels.

Is Elanco Animal Health, Inc. overvalued or undervalued?

2025-10-21 12:10:38

As of 17 October 2025, the valuation grade for Elanco Animal Health, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 14, an EV to EBITDA of 12.07, and a PEG ratio of 0.03, which suggests limited growth relative to its price. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of approximately 19.25 and 15.17, respectively, indicating that Elanco's valuation is less favorable in the context of its industry. Despite strong recent performance, with a year-to-date return of 76.88% compared to the S&P 500's 13.30%, the long-term outlook appears less optimistic, as evidenced by a 5-year return of -32.09% against the S&P's 91.29%. This disparity in long-term performance further supports the conclusion that Elanco Animal Health, Inc. is currently ove...

Elanco Animal Health Experiences Valuation Adjustment Amid Competitive Market Dynamics

2025-10-20 17:18:56

Elanco Animal Health, Inc. has recently adjusted its valuation, reflecting changes in financial metrics within the Pharmaceuticals & Biotechnology sector. The company reports a P/E ratio of 14 and a price-to-book value of 1.09, with notable returns on capital and equity. Its year-to-date stock performance has significantly outpaced the S&P 500.

Is Elanco Animal Health, Inc. overvalued or undervalued?

2025-10-20 12:27:52

As of 17 October 2025, Elanco Animal Health, Inc. has moved from a very attractive valuation grade to expensive. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 12.07, and a Price to Book Value of 1.09. In comparison to peers, Elanco's P/E ratio of 19.25 is higher than BioMarin Pharmaceutical, Inc., which has a P/E of 15.17, indicating that Elanco is trading at a premium relative to some of its competitors. Despite strong short-term returns, with a year-to-date return of 76.88% compared to the S&P 500's 13.30%, the long-term performance has been lackluster, with a 5-year return of -32.09% versus the S&P 500's 91.29%. This disparity suggests that while recent performance may seem promising, the overall valuation does not support continued growth at the current price levels....

Is Elanco Animal Health, Inc. overvalued or undervalued?

2025-10-19 12:05:22

As of 17 October 2025, the valuation grade for Elanco Animal Health, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued, with a P/E ratio of 14, an EV to EBITDA ratio of 12.07, and a PEG ratio of 0.03, which suggests that while growth expectations are low, the current price may not reflect its intrinsic value adequately. In comparison to its peers, Elanco's P/E ratio of 19.25 is higher than BioMarin Pharmaceutical, Inc. at 15.17, which is considered fairly valued, and significantly higher than Halozyme Therapeutics, Inc. at 15.92. Despite strong recent performance, with a year-to-date return of 76.88% compared to the S&P 500's 13.30%, the long-term outlook appears less favorable, as the 5-year return for Elanco is -32.09% versus the S&P 500's 91.29%. This discrepancy reinforces the notion that Elanco may be overvalued at its curr...

Elanco Animal Health Hits New 52-Week High at $21.76

2025-10-08 16:58:06

Elanco Animal Health, Inc. achieved a new 52-week high of USD 21.76 on October 7, 2025, reflecting a strong upward trend from its low of USD 8.02. The company, with a market cap of approximately USD 9,464 million, operates in the Pharmaceuticals & Biotechnology sector and emphasizes growth.

View All News